|
||||||||
![]() |
||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]()
|
Gateway® |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() Download
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
| attL 1 site | Bgl II | Sac I | EcoR I | Sal I | Sac II | Sma I/Xma I | Age I | TagRFP | ||||||||||||||||||||||
| Afe I | Xho I | Hind III | Pst I | Kpn I | Apa I | BamH I | Nco I* | |||||||||||||||||||||||
| ...AGG.CTG. | CT | A.GCG.CT | A.CCG.GAC.TC | A.GAT. | CT | C. | GAG | .CTC | . | AAG.CTT | .C | GA.ATT. | C | TG.CA | G | .TCG.AC | G.GTA. | CC | G.C | GG | .G | CC.C | G | G.G | AT.CC | A.CCG.GT | C.GCC.A | CC. | ATG.G | ... |
* - not unique site.
Gateway® TagRFP-AS-N entry clone is a vector containing red (orange) fluorescent protein TagRFP gene variant with codon usage optimized for high expression in Arabidopsis and Saccharomyces. TagRFP coding sequence is flanked by attL1 and attL2 sites allowing easy site-specific recombination. The Invitrogen Gateway® Technology provides a rapid and highly efficient way to transfer the TagRFP gene into a number of Gateway® destination vectors for expression in different experimental systems. Multiple cloning site (MCS) located at the 5'-end of TagRFP gene allows to generate fusions to the TagRFP N-terminus for expression, localization and cellular dynamics studies.
To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of TagRFP coding sequence [Kozak, 1987].
The vector backbone contains pUC origin of replication and kanamycin resistance gene (Kanr) for propagation and selection in E. coli.
Generation of TagRFP-tagged fusions
A localization signal or a gene of interest can be cloned into MCS of the vector both before and after site-specific recombination with a destination vector. It will be expressed as a fusion to the TagRFP N-terminus when inserted in the same reading frame as TagRFP and no in-frame stop codons are present.
Alternatively, TagRFP gene can be fused to the 3'-end of a gene of interest by LR recombination of the Gateway® TagRFP-AS-N with a destination vector containing this gene in a correct reading frame.
TagRFP-tagged fusions retain fluorescent properties of the native protein allowing fusion localization in vivo.
Note: The plasmid DNA was isolated from dam+-methylated E.coli. Therefore some restriction sites are blocked by methylation. If you wish to digest the vector using such sites you will need to transform the vector into a dam- host and make fresh DNA.
LR site-specific recombination
Please refer to Invitrogen Gateway® Technology description for detailed instructions regarding LR site-specific recombination reaction. In general, to transfer TagRFP gene or TagRFP-fusion construct into the destination vector you will need:
- Purified plasmid DNA of Gateway® TagRFP-AS-N
- A destination vector of choice
- Invitrogen LR ClonaseTM II enzyme mix (Invitrogen Cat.# 11791-020)
- Proteinase K solution (supplied with the LR ClonaseTM II enzyme mix)
- TE-Buffer, pH 8.0 (10 mM Tris-HCl, pH 8.0, 1 mM EDTA)
- Appropriate chemically competent E. coli host and growth media for expression
- Appropriate selective plates.
Propagation in E. coli
Suitable host strains for propagation in E. coli include DH5alpha, HB101, XL1-Blue, and other general purpose strains. Plasmid incompatibility group is pMB1/ColE1. The vector confers resistance to kanamycin (30 μg/ml) to E. coli hosts. Copy number in E. coli is about 500.
Location of features
attL1 site: 14-113
MCS: 117-194
Kozak translation initiation site: 195-205
TagRFP-AS: 202-915
attL2 site: 934-1033
Kanamycin resistance gene: 2251-3045
pUC origin of replication: 3630-4273
Evrogen Fluorescent Protein Products (the Products) are intended for research use only and covered by Evrogen Patents and/or Patent applications pending. By use of these products, you accept the terms and conditions of the applicable Limited Use Label License.
Invitrogen Gateway® Technology: please see Limited Use Label License No. 19: Gateway® Cloning Products.
To the best of our knowledge, these products do not require a Material Safety Data Sheet. However, all the properties of these products (and, if applicable, each of their components) have not been thoroughly investigated. Therefore, we recommend that you use gloves and eye protection, and wear a laboratory coat when working with these products.
|
Copyright 2002-2008 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, +7(495)4298020, e-mail:evrogen@evrogen.com |